Community Decision: Schistosomiasis Mass Treatment Frequency (WHO 2022)
A community program decision on schistosomiasis mass treatment by WHO 2022: yearly praziquantel from 10% prevalence (30% by POC-CCA), twice yearly after a poor response, and options under 10%.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Community prevalence, %
- 25
- Measured by
- Kato-Katz (stool)
- Regular preventive chemotherapy already given
- Yes
Result: Yearly mass treatment with single-dose praziquantel at 75% coverage or more (moderate prevalence, 25%).
The tool opens with these values already filled in. Replace them with your own.
What you enter
- Community prevalence, %
- Measured by
- Regular preventive chemotherapy already given
- Baseline prevalence before mass treatment, % (optional)
- Two yearly rounds given at 75% coverage or more
How this is calculated
Citation
WHO guideline on control and elimination of human schistosomiasis. Geneva: WHO; 2022. Recommendations 1-3 and the glossary (pp. ix-xviii). Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.